

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/98491>

Please be advised that this information was generated on 2019-09-17 and may be subject to change.

Treatment with Anakinra Improves Disposition Index But Not Insulin Sensitivity in Nondiabetic Subjects with the Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

Edwin J. P. van Asseldonk, Rinke Stienstra, Tim B. Koenen, Leo A. B. Joosten, Mihai G. Netea, and Cees J. Tack

Department of Internal Medicine, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands

Context: Obesity induces low-grade inflammation that may promote the development of insulin resistance. IL-1 is one of the key inflammatory factors.

Objective: The objective of the study was to demonstrate improvement of insulin sensitivity by blocking IL-1.

Design: This was a randomized, double-blind, crossover study.

Setting: The study was based on ambulatory care.

Participants: Participants included nondiabetic, obese subjects with the metabolic syndrome.

Intervention: Intervention included 150 mg anakinra sc once daily or matching placebo for 4 wk.

Main Outcome Measure: Insulin sensitivity as measured by euglycemic hyperinsulinemic clamp.

Results: A total of 13 of 19 subjects completed the study. Although anakinra treatment resulted in a significantly lower level of inflammation illustrated by a reduction in circulating C-reactive protein concentrations and leukocyte numbers, insulin sensitivity was not significantly different after anakinra treatment ($2.8 \times 10^{-2} \pm 0.5 \times 10^{-2}$) compared with placebo treatment ($2.4 \times 10^{-2} \pm 0.3 \times 10^{-2} \mu\text{mol/kg}^{-1} \cdot \text{min}^{-1} \cdot \text{pmol}^{-1}$, $P = 0.15$). Adipose tissue examination, performed to analyze local effects of IL-1 receptor antagonist, showed an increased influx of macrophages after treatment with anakinra most likely due to an injection site reaction caused by the vehicle (0.28 ± 0.05 vs. 0.11 ± 0.01 macrophages per adipocyte, $P = 0.005$). The differences in individual subject insulin sensitivity after anakinra as compared with placebo between subjects were negatively correlated with macrophage infiltration into the adipose tissue ($r^2 = 0.46$, $P = 0.01$). The disposition index increased significantly after anakinra treatment ($P = 0.04$), reflecting an improvement in β -cell function.

Conclusions: Our results suggest that anakinra does not improve insulin sensitivity in obese, insulin-resistant, nondiabetic subjects. (*J Clin Endocrinol Metab* 96: 2119–2126, 2011)

The global prevalence of obesity is rapidly rising and paralleled by an increasing incidence of insulin resistance and type 2 diabetes mellitus. Although the pathophysiological basis underlying obesity-associated

insulin resistance has not been fully unraveled, many reports suggest that chronic low-grade inflammation originating from adipose tissue represents an important link (1).

ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.

Copyright © 2011 by The Endocrine Society

doi: 10.1210/jc.2010-2992 Received December 21, 2010. Accepted March 28, 2011.

First Published Online April 20, 2011

Abbreviations: CD68, Cluster of differentiation 68; CI, confidence interval; FABP4, fatty acid binding protein 4; HbA1c, glycosylated hemoglobin; hsCRP, high-sensitivity C-reactive protein; IL-1R, IL-1 receptor; IL-1Ra, IL-1 receptor antagonist; OGTT, oral glucose tolerance test; PPAR, peroxisome proliferator-activated receptor.

Storage of excess energy results in expansion of adipose tissue mass and an increase in adipocyte size. Concurrent with this expansion, oxygen delivery to the adipocyte is decreased and may eventually lead to microhypoxia and adipocyte death. Together with the enhanced proinflammatory profile of enlarged adipocytes (2), this results in the recruitment of macrophages that further amplify the inflammatory status of the adipose tissue (3). Proinflammatory cytokines such as TNF α and IL-6 that are released in increased amounts by adipocytes and activated macrophages of obese individuals can induce insulin resistance (4, 5).

The proinflammatory cytokine IL-1 is also involved in the development of diabetes mellitus. By inducing β -cell destruction, IL-1 contributes to the pathogenesis of type 1 diabetes mellitus (6). Furthermore, a positive association between IL-1 levels and the presence of obesity has been found (7). IL-1 β induces insulin resistance in cultured human adipocytes (8) and primary rat hepatocytes (9), and IL-1 β knockout mice are more insulin sensitive as their wild-type littermates (10, 11). Based on these observations, one might expect that blockade of IL-1 β would improve insulin resistance in humans.

IL-1 exerts its effects by binding to the type 1 IL-1 receptor (IL-1R) (12). This results in recruitment of IL-1 receptor accessory protein, necessary for signal transduction (13). Activation of IL-1R leads to fever, synthesis of acute phase proteins, leukocytosis, thrombocytosis, and anemia (14). IL-1 receptor antagonist (IL-1Ra) inhibits IL-1 action by competing with IL-1 for binding to the IL-1R. Binding of IL-1Ra to the IL-1R does not result in recruitment of IL-1 receptor accessory protein and thereby blocks intracellular signaling (13).

Blocking the IL-1 effects in patients with type 2 diabetes mellitus by anakinra, a recombinant human IL-1Ra, has been shown to improve glycemic control (15). Whether IL-1 blockade has a beneficial effect on insulin sensitivity in nondiabetic subjects characterized by insulin resistance remains to be determined.

In the present study, we investigated whether blocking IL-1 by recombinant IL-1Ra in humans for 4 wk can improve insulin sensitivity in nondiabetic, obese subjects with the metabolic syndrome.

Subjects and Methods

Study design

Overweight subjects with the metabolic syndrome, yet no type 2 diabetes mellitus, were included in this randomized, double-blind, placebo-controlled, two-period, crossover study. Subjects were recruited by means of advertisements in a local newspaper and from the outpatient clinic of the Radboud University

Nijmegen Medical Centre. We compared anakinra with matching placebo. Study medication was self-administrated sc once daily for 4 wk. Between both treatment periods, there was a 4-wk washout. Because prior studies suggest that the conventional dose of 100 mg anakinra once daily is not sufficient in patients with high body weight (15), the dose was increased to 150 mg daily. This dose has been applied in patients with rheumatoid arthritis (16).

Anakinra was purchased from the regular manufacturer (Biovitrum, Stockholm, Sweden). The Pharmacy Department of Radboud University Nijmegen Medical Centre prepared all study medication and was responsible for the blinding and randomization procedure. Subjects were randomized in blocks of four in a 1:1 allocation ratio.

Participants

The study was approved by the institutional ethics review board and assessed by an independent monitor. Written informed consent was obtained from all subjects before randomization.

Inclusion criteria were age 18 yr or older, body mass index greater than 30 kg/m², and three or more characteristics of the metabolic syndrome according to the definition of the third report of the National Cholesterol Education Program's Adult Treatment Panel (17). Exclusion criteria were the known presence of diabetes mellitus, a fasting plasma glucose 7.0 mmol/liter or higher, glycosylated hemoglobin (HbA1c) 6.2% or higher, immunodeficiency or immunosuppressive treatment, current use of antiinflammatory medication (\leq 100 mg aspirin per day was allowed), signs of current infection or treatment with antibiotics, a history of recurrent infections or tuberculosis, pregnancy or breast-feeding, a serum alanine aminotransferase or aspartate aminotransferase level of more than 3 times the upper limit of the normal range, a serum creatinine level higher than 130 μ mol/liter, neutropenia (a leukocyte count of less than 2×10^9 /liter), or the presence of any other medical condition that might interfere with the current study protocol and inability to give informed consent.

Study procedures

At the end of both treatment periods, we performed a euglycemic hyperinsulinemic clamp (insulin infusion rate 360 pmol/m² · min (18) and on a separate day a 75-g oral glucose tolerance test.

A sc fat biopsy was obtained. All study procedures were performed after an overnight fast.

Subcutaneous adipose tissue biopsy

A sc adipose tissue biopsy was taken just before the clamp, about 30 min after a sc injection with placebo or anakinra to analyze local effects of the active substance (recombinant IL-1Ra) of anakinra. Biopsies were taken under local anesthesia (2% Lidocaine HCl) from an area that was not affected by a local injection site reaction caused by the vehicle of anakinra, about 10 cm lateral of the umbilicus using a Hepafix Luer lock syringe (Braun, Melsungen, Germany) and a 2.10- \times 80-mm Braun medical Sterican needle (Braun). The adipose tissue was washed using a 0.9% normal saline solution. The adipose tissue was snap fro-

zen and stored at -80°C until further analysis or fixated in 4% paraformaldehyde for embedding in paraffin.

Immunohistochemistry

An antibody against the cluster of differentiation 68 (CD68; AbD Serotec, Kidlington, UK) was used to stain macrophages. Immunohistochemistry was performed as described earlier (19). Macrophage influx was quantified by counting the number of adipocytes and macrophages in four representative fields of adipose tissue. A mean number of 609 ± 24 adipocytes were counted per subject for each treatment period.

RNA isolation and real-time PCR analysis

Total RNA was extracted from sc adipose tissue using TRIzol reagent (Invitrogen, Carlsbad, CA). RNA concentration was determined using the NanoDrop (NanoDrop Technologies, Wilmington, MA). cDNA synthesis was performed using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). Real-time PCR was performed using Power-SYBR Green master mix and the 7300 real-time PCR system (Applied Biosystem, Warrington, UK). Expression of genes was normalized to $\beta 2M$ gene expression levels. Used primer sequences were: $\beta 2M$, ATGAGTATGCCTGCCGTGTG (sense), CCAAATGCGGCATCTTCAAAC (antisense); peroxisome proliferator-activated receptor (*PPAR* γ), ATTGACCCA-GAAAGCGATTCC (sense), TCTTCCATTACGGAGAG, ATCCAC (antisense); fatty acid binding protein 4 (*FABP4*), AGCACATAACCTTAGATGGGG (sense), CGTGGAAGTGACGCCTT-TCA (antisense); *adiponectin*, ATCGGTGAAACCGGAGTACC (sense), GCATGTTGGGGATAGTAACGTAA (antisense).

Biochemical analysis

Glucose concentrations were measured using the oxidation method (Glucose Analyzer 2; Beckman Instruments Inc., Fullerton, CA). Plasma concentrations of total adiponectin, IL-6, IL-1Ra, high-sensitivity C-reactive protein (hsCRP), and proinsulin were determined using ELISA [R&D Systems, Minneapolis, MN; proinsulin: Millipore, Billerica, MA; hsCRP in-house developed ELISA by University Hospital Maastricht (20)]. Insulin levels were determined by a RIA. For C-peptide determination, chemiluminescence was used. Inter- and intraassay coefficients of variation were, respectively: adiponectin, 2.7 and 1.3%; IL-6, 3.3 and 5.0%; IL-1ra, 5.0 and 8.0%; hsCRP, 4.7 and 3.8%; insulin, 9.7 and 4.7%; and proinsulin 4.7 and 5.6%.

Measurements of other parameters were performed in the clinical laboratory unit of the Radboud University Nijmegen Medical Centre.

Statistical analysis

We considered a 20% improvement of the primary end point, insulin sensitivity, as determined by euglycemic hyperinsulinemic clamp, as clinically relevant. Assuming a test-to-test correlation coefficient of 0.5 (paired tests) and a mean glucose infusion rate of $30 \pm 7 \mu\text{mol/kg/min}$ would require a total of 11 subjects to detect a 20% change in insulin sensitivity with a power of 80% at a significance level of 0.05. Dropouts were replaced.

Differences were analyzed by the Student's *t* test. Correlation analysis was performed by regression analysis. Two-tailed $P \leq 0.05$ was considered to denote significance. Data are presented as mean \pm SEM.




FIG. 1. Design, enrollment, withdrawal, and completion of the study.

Results

Nineteen of the 32 initially screened subjects underwent randomization and were enrolled in the study between June and October of 2009. A total of 13 subjects, nine females and four males, completed the study. Nine of the 13 subjects who completed the study used anakinra in the second treatment period. Two of the six dropouts used anakinra in the second treatment period. Two subjects were discontinued from the study due to an infection, one had an H1N1 infection (during anakinra treatment) and one had a wound infection (during placebo treatment in the first treatment period). Two subjects withdrew due to the physical load of the tests and two subjects withdrew due to injection site reactions (Fig. 1). Dropouts were significantly younger ($P = 0.008$), had a higher body mass index ($P = 0.02$), and had a larger waist circumference ($P = 0.05$) in comparison with study subjects that completed the study. All other parameters were similar between study subjects that withdrew or completed the study.

The trial was terminated after the last subject completed all studies in February 2010. Baseline characteristics of all subjects that completed the study are shown in Table 1.

Twelve of 13 subjects experienced local injection site reactions (Fig. 2B) of varying severity. No other adverse

TABLE 1. Baseline characteristics of the participants

Characteristic	
Age	53.6 ± 2.8
Sex (male:female)	4: 9
Body mass index (kg/m ²)	33.2 ± 1.3
Waist circumference (cm)	110.5 ± 3.2
Blood pressure (mm Hg)	
Systolic	143.8 ± 2.8
Diastolic	83.3 ± 2.5
Fasting glucose (mmol/liter)	5.49 ± 0.15
HbA1c (%)	5.58 ± 0.09
CRP (mg/liter)	5.62 ± 0.08
Hemoglobin (mmol/liter)	8.48 ± 0.18
Leucocytes (× 10 ⁹ /liter)	6.49 ± 0.54
Cholesterol (mmol/liter)	
Total	5.68 ± 0.32
HDL	1.02 ± 0.07
LDL	3.63 ± 0.30
Triglycerides	2.85 ± 0.50
IL-1Ra (μg/liter)	0.76 ± 0.14
HOMA-IR (mmol/pmol)	5.67 ± 0.64
Medication with antiinflammatory effects (number of study subjects)	
Simvastatin (20 mg/d)	3
Atorvastatin (40 mg/d)	
Lisinopril (20 mg/d)	
Aspirin (100 mg/d)	1

CRP, C-reactive protein; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; HOMA-IR, homeostasis model assessment insulin resistance index.

events were observed during the study. Sufficiency of the intervention was assessed by measuring serum and adipose tissue levels of IL-1Ra. The serum levels of IL-1Ra 30 min after the last injection of anakinra or placebo were 735 ± 86 after anakinra and 0.7 ± 0.1 μg/liter after placebo, $P < 0.001$. Levels of IL-1Ra in adipose tissue lysates were 29.2 ± 7.5 after anakinra and 1.8 ± 0.4 ng/liter after placebo, corrected for protein levels, $P < 0.05$. There were no carry-over effects detected.

Systemic inflammation

Inasmuch IL-1Ra has been attributed with antiinflammatory effects (21), we measured several markers indicative of systemic inflammation. hsCRP levels (anakinra 3.57 ± 1.40 vs. placebo 5.37 ± 1.78 mg/liter, $P = 0.05$) (Fig. 3A) and leukocyte counts (anakinra 5.32 ± 0.41 vs. placebo $6.39 \pm 0.57 \times 10^9$ /liter, $P = 0.002$) (Fig. 3B) were significantly reduced in study subjects after anakinra treatment.

Insulin sensitivity and β-cell function

Although participants were clearly insulin resistant as illustrated by an insulin sensitivity index of $2.4 \times 10^{-2} \pm 0.3 \times 10^{-2}$ μmol/kg⁻¹ · min⁻¹ · pmol⁻¹ insulin after placebo treatment (normal range in lean subjects 4.0 – 7.0×10^{-2} μmol/kg⁻¹ · min⁻¹ · pmol⁻¹ insulin) (22), treatment with




FIG. 2. Effects of anakinra on insulin sensitivity and adipose tissue. A, Insulin sensitivity index after treatment with placebo and anakinra are represented for each individual participant; black dashes represent mean values. B, Injection site reaction as experienced by one of the participants of the study. C, CD68 staining images of sc adipose tissue of an individual participant after placebo and after anakinra treatment. D, Correlation of the change in insulin sensitivity index after anakinra treatment compared with placebo with the severity of macrophage infiltration into the adipose tissue after anakinra treatment compared with placebo.

anakinra for 4 wk did not result in an improvement in insulin sensitivity (anakinra $2.8 \times 10^{-2} \pm 0.5 \times 10^{-2}$ vs. placebo $2.4 \times 10^{-2} \pm 0.3 \times 10^{-2}$ μmol/kg⁻¹ · min⁻¹ · pmol⁻¹ insulin, $P = 0.15$) (Fig. 2A). Average HbA1c (anakinra $5.57 \pm$




FIG. 3. Effect of anakinra on inflammation and β-cell function. hsCRP (A) and leukocyte count (B) after treatment with placebo and anakinra are shown. C, Disposition index, calculated as the change in circulating insulin concentration during the first 30 min of the OGTT, divided by the change in the circulating glucose concentration during the first 30 min of the oral glucose tolerance test. D, Area under the curve for C-peptide during the OGTT. E, Fasting proinsulin to insulin ratio. Data are represented as mean ± SEM. *, $P < 0.05$; **, $P < 0.01$.

0.11 *vs.* placebo $5.62 \pm 0.08\%$, $P = 0.35$) and fasting glucose (anakinra 5.34 ± 0.13 *vs.* placebo 5.46 ± 0.15 mmol/liter, $P = 0.17$) levels were unchanged after anakinra treatment. Inasmuch no stable isotopes were used during the clamp, we were unable to determine the effects of anakinra treatment on liver insulin sensitivity levels. Alternatively, liver insulin sensitivity was estimated by using data obtained during the oral glucose tolerance test (OGTT) (23). Liver insulin sensitivity was not different between placebo *vs.* anakinra treatment ($P = 0.66$).

The disposition index during the OGTT [change in insulin (0–30 min)/change in glucose (0–30 min)] improved after anakinra treatment, $P = 0.04$ (Fig. 3C), suggestive for a somewhat enhanced β -cell function. However, other parameters indicative for β -cell function including stimulated C-peptide levels (area under the curve during the OGTT) (Fig. 3D) and fasting proinsulin to insulin ratio (Fig. 3E) did not differ significantly between placebo and anakinra treatment. Raw OGTT data are represented in Supplemental Fig. 1, published on The Endocrine Society's Journals Online web site at <http://jcem.endojournals.org>.

Based on OGTT criteria, five of the study participants had impaired glucose tolerance. In this group no statistically significant differences in insulin sensitivity or β -cell function were found, perhaps based on the small sample size.

No significant differences in triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total cholesterol were present between placebo and anakinra treatment.

Adipose tissue

The systemic low-grade inflammatory reaction characteristic for obesity is mainly inflicted by inflammation in the adipose tissue (3). The inhibition of IL-1 by IL-1Ra (active substance of anakinra) is expected to reduce this inflammatory reaction. However, the vehicle of anakinra is known to induce an injection site reaction during the first weeks of treatment in a majority of patients (16). We performed fat biopsies to study the local effects of anakinra treatment in abdominal sc adipose tissue.

Immunohistochemical visualization of macrophages using CD68 staining revealed an increased number of macrophages in the adipose tissue after anakinra treatment (0.28 ± 0.05 *vs.* 0.11 ± 0.01 macrophages per adipocyte, $P = 0.005$) (Fig. 2C). In addition, IL-6 concentrations in adipose tissue tended to be higher after anakinra treatment (anakinra 26.9 ± 12.4 $\mu\text{g/g}$ adipose tissue *vs.* placebo 5.7 ± 1.2 $\mu\text{g/g}$ adipose tissue, $P = 0.07$), suggestive of an enhancement in inflammatory properties of the adipose tissue. Moreover, expression levels of adipogenic genes determined by quantitative PCR analysis in sc adi-

pose tissue revealed significantly decreased levels of *PPAR* γ ($P = 0.03$) and *FABP4* ($P = 0.04$), whereas *adiponectin* tended to decrease ($P = 0.07$) after anakinra treatment.

The severity of the inflammatory reaction in the abdominal sc adipose tissue, reflected by the number of infiltrating macrophages after anakinra treatment, was negatively correlated with the difference in individual subject insulin sensitivity level after anakinra treatment ($R^2 = 0.46$, $P = 0.01$) (Fig. 2D).

Subgroup analysis, using an increase in macrophage influx of greater than 300% after anakinra treatment as a cutoff point, unveiled that in study subjects with low levels of infiltrating macrophages, insulin sensitivity after anakinra treatment improved significantly by $39 \pm 9\%$ [95% confidence interval (CI) 18–61%, $P = 0.003$] compared with placebo, whereas in subjects with more than a 3-fold increase in infiltrating macrophages, insulin sensitivity decreased by $-14 \pm 12\%$ (95% CI -47 to 19%, $P = 0.31$). The average insulin sensitivity of subjects with low macrophage influx was 53% (95% CI 20–86%, $P = 0.006$) better as compared with subjects with high macrophage influx. Levels of circulating hsCRP were comparable in both groups. Adipose tissue IL-6 appeared lower in subjects with no or mild infiltration of macrophages compared with the subjects with extensive infiltration, although the difference did not attain statistical significance (13.7 ± 5.9 *vs.* 53.2 ± 34.4 $\mu\text{g/g}$ adipose tissue, $P = 0.14$).

Discussion

The present study did not find an improvement in insulin sensitivity after 4 wk of treatment with the IL-1Ra anakinra in an insulin-resistant population. The selected study population enabled us to analyze the effects of an anti-inflammatory intervention on insulin sensitivity without the potential interference of antidiabetic medication and the confounding effects of changing glycemic control.

In accordance with earlier findings in a population of type 2 diabetic patients (15), we were unable to detect an improvement in insulin sensitivity after anakinra treatment our study population. However, an animal study using XOMA 052 (anti-IL-1 β antibody) has reported a positive effect on both insulin sensitivity and β -cell function (11). Another animal study using 1400.24.17 (anti-IL-1 β antibody) showed reduced HbA1c after 18 wk of treatment without consistent improvements in insulin sensitivity and glucose tolerance (24). An important difference between the animal studies *vs.* the human trial of Larsen *et al.* (15) and our trial is the use of specific anti-

IL-1 β antibodies in the animal trials. The human trials do use IL-1Ra, which has effects on both IL-1 α and IL-1 β .

There are a number of explanations for the lack of improvement in insulin sensitivity in our study.

First, circulating levels of IL-1Ra in study participants may vary considerably. It has been suggested that IL-1Ra levels at baseline determine the effects of anakinra treatment, with those with the lowest level showing the highest response (25). Nevertheless, in our study we were unable to find any association between IL-1Ra levels at baseline and changes in insulin sensitivity after anakinra treatment, which largely excludes the possibility that insufficient production of IL-1Ra contributes to the development of insulin resistance in our study subjects. Noticeably, also in our population, the baseline IL-1Ra levels were quite variable.

Second, the dose of IL-1Ra used in our study or infiltration into target tissues may have been insufficient. However, the dosage used in our study was 1.5 times higher than normally used and concentrations of IL-1Ra in the circulation were 1000-fold higher compared with placebo treatment, accompanied by a 16-fold increase in IL-1Ra levels in adipose tissue after anakinra treatment. Moreover, the reduction in inflammatory markers including hsCRP and leukocytes suggest that treatment with anakinra did provoke a systemic antiinflammatory effect.

Third, because adipose tissue is a causative factor for systemic low-grade inflammation during the development of obesity (3) and is partly responsible for determining systemic insulin sensitivity, we evaluated local effects of anakinra in adipose tissue biopsies. Based on earlier results of *in vitro* studies that demonstrated lower insulin sensitivity and reduced levels of the adipogenic markers *PPAR γ* and *FABP4* after IL-1 β treatment of adipocytes, we hypothesized that inhibiting IL-1 signaling by anakinra treatment would enhance adipogenic gene expression levels (8, 26). In contrast, anakinra treatment led to reduced gene expression levels of *PPAR γ* and *FABP4* and increased levels of macrophage infiltration. This finding is surprising because treatment with anakinra reduced systemic levels of inflammation. The influx of macrophages, probably accompanied by other immune cells, is most likely not the direct effect of IL-1Ra but might be the effect of one of the additives present in the commercial preparations of anakinra. Injection site reaction is a well-known side effect of anakinra during the first weeks of treatment and is known to result in the infiltration of macrophages (27). Earlier studies have demonstrated the importance of infiltrating macrophages in the sc adipose tissue in provoking systemic insulin resistance (28). The lack of positive findings of our study on insulin sensitivity may thus (partly) be explained by negative effects of local adipose

tissue inflammatory injection site reactions on insulin sensitivity. In line with this explanation, the severity of the inflammatory reaction caused by the injection site reaction in sc adipose tissue turned out to be inversely correlated with the improvement in systemic insulin sensitivity after anakinra treatment.

The relation between IL-1, inflammation in adipose tissue, and its effect on systemic insulin sensitivity by affecting systemic inflammation is well known. However, in this study local inflammation in the abdominal sc adipose tissue is correlated with systemic insulin sensitivity, without influencing systemic inflammation. This can partly be explained by a direct negative effect of local inflammation on the local adipose tissue. Alternatively, the inflamed adipose tissue might have led to an altered adipokine secretion profile that negatively interfered with insulin sensitivity in peripheral organs including liver and muscle.

It should be stressed that the adipose tissue biopsy was not taken out of an area with macroscopic inflammation. However, because injection sites were varied over time (as advised) over different abdominal areas, the diffuse inflammation observed may reflect tissue responses from earlier injections.

In respect to β -cell function, we found a hint toward improved insulin secretion capacity as reflected by the disposition index, although the other evaluated parameters for β -cell function did not improve significantly. However, the disposition index is known to be an independent predictor for the development of type 2 diabetes mellitus (29). It should also be stressed that the participants in this study were selected for insulin resistance (obesity/metabolic syndrome) but not insulin secretion deficits. All subjects had glucose levels in the nondiabetic range.

This is the first study that has specifically studied the effects of IL-1 blockade on insulin sensitivity in human nondiabetic subjects. A similar study has been performed in subjects with type 2 diabetes (15). This latter study measured both insulin sensitivity and insulin secretion before and after 13 wk of treatment. Glycemic control improved after 4 and 13 wk of treatment, and this was attributed to an improvement in β -cell function, whereas insulin sensitivity appeared to be unchanged. As such, our findings are in line with the results of the study performed by Larsen *et al.* (15). The fact that we did not find a clear improvement in insulin secretion may be explained by the differences in study population. The subjects included in our study were nondiabetic and had normal levels of HbA1c and fasting glucose at baseline and had no indication of defective β -cell function, whereas Larsen *et al.* included patients with type 2 diabetes mellitus.

The dose and duration of treatment were different in our study compared with Larsen *et al.* (15) (100 mg sc once

daily for 13 wk by Larsen *et al.* vs. 150 mg sc once daily for 4 wk in our study). The larger dose and shorter treatment period used in our study may have aggravated the injection site reaction because adverse effects are dose dependent and vanish after prolonged treatment (16). Theoretically a prolonged treatment of subjects in our study could have resulted in waning of side effects because injection site reactions of anakinra do disappear after 4–6 wk of treatment and may have revealed an improvement in insulin sensitivity. However, a prolonged treatment period would substantially extend the duration of the (cross-over) trial, increasing the risk for carry-over effects, whereas biological effects of IL-1 blockade were expected to be present within weeks.

In summary, the results of this study do not support the concept that blockade of IL-1 by anakinra treatment improves insulin sensitivity. It cannot be fully excluded, though, that potentially positive effects on insulin sensitivity are (partly) offset by local inflammatory reactions at the injection site of anakinra. Whether treatment with other modalities that block IL-1 but do not produce local injection site effects potentially has a beneficial effect on insulin sensitivity remains to be determined. The present study results support a beneficial effect of blocking IL-1 on β -cell function.

Acknowledgments

Microscopy was performed at the Microscopic Imaging Centre of the Radboud University Nijmegen Medical Centre. The assistance of research nurses, laboratory analysts, and clinical pharmacy employees of the Radboud University Nijmegen Medical Centre was highly appreciated. The clinical trial registration number is NCT00928876 (www.Clinicaltrials.gov).

Address all correspondence and requests for reprints to: E. J. P. van Asseldonk, Department of Internal Medicine 463, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: e.vanasseldonk@aig.umcn.nl.

This work was supported by a grant from the European Association for the Study of Diabetes and the Dutch Diabetes Research Foundation. M.G.N. was supported by a Vici grant from The Netherlands Organization for Scientific Research.

Disclosure Summary: All authors declare no conflict of interest.

References

1. Kahn SE, Hull RL, Utzschneider KM 2006 Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 444:840–846
2. Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, Kotani H, Yamaoka S, Miyake K, Aoe S, Kamei Y, Ogawa Y 2007 Role of the Toll-like receptor 4/NF- κ B pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. *Arterioscler Thromb Vasc Biol* 27:84–91
3. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 112:1821–1830
4. Hotamisligil GS, Shargill NS, Spiegelman BM 1993 Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science* 259:87–91
5. Fried SK, Bunkin DA, Greenberg AS 1998 Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. *J Clin Endocrinol Metab* 83:847–850
6. Mandrup-Poulsen T, Zumsteg U, Reimers J, Pociot F, Mørch L, Helqvist S, Dinarello CA, Nerup J 1993 Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic β -cell destruction in insulin-dependent diabetes mellitus. *Cytokine* 5:185–191
7. Bunout D, Muñoz C, López M, de la Maza MP, Schlesinger L, Hirsch S, Pettermann M 1996 Interleukin 1 and tumor necrosis factor in obese alcoholics compared with normal-weight patients. *Am J Clin Nutr* 63:373–376
8. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulangé A, Capeau J, Caron M 2006 Long-term treatment with interleukin-1 β induces insulin resistance in murine and human adipocytes. *Diabetologia* 49:2162–2173
9. Nov O, Kohl A, Lewis EC, Bashan N, Dvir I, Ben-Shlomo S, Fishman S, Wueest S, Konrad D, Rudich A 2010 Interleukin-1 β may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation. *Endocrinology* 151:4247–4256
10. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, Rensen PC, Voshol PJ, Fantuzzi G, Hijmans A, Kersten S, Müller M, van den Berg WB, van Rooijen N, Wabitsch M, Kullberg BJ, van der Meer JW, Kanneganti T, Tack CJ, Netea MG 2010 The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. *Cell Metab* 12:593–605
11. Owyang AM, Maedler K, Gross L, Yin J, Esposito L, Shu L, Jadhav J, Domsgen E, Bergemann J, Lee S, Katak S 2010 XOMA 052, an anti-IL-1 β monoclonal antibody, improves glucose control and β -cell function in the diet-induced obesity mouse model. *Endocrinology* 151:2515–2527
12. Sims JE, March CJ, Cosman D, Widmer MB, MacDonald HR, McMahon CJ, Grubin CE, Wignall JM, Jackson JL, Call SM 1988 cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. *Science* 241:585–589
13. Greenfeder SA, Varnell T, Powers G, Lombard-Gillooly K, Shuster D, McIntyre KW, Ryan DE, Levin W, Madison V, Ju G 1995 Insertion of a structural domain of interleukin (IL)-1 β confers agonist activity to the IL-1 receptor antagonist. Implications for IL-1 bioactivity. *J Biol Chem* 270:22460–22466
14. Dinarello CA 2005 Blocking IL-1 in systemic inflammation. *J Exp Med* 201:1355–1359
15. Larsen CM, Faulenbach M, Vaag A, Vølund A, Eshes JA, Seifert B, Mandrup-Poulsen T, Donath MY 2007 Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *N Engl J Med* 356:1517–1526
16. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P 1998 Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum* 41:2196–2204
17. 2001 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 285:2486–2497
18. Abbink EJ, De Graaf J, De Haan JH, Heerschap A, Stalenhoef AF,

- Tack CJ 2006 Effects of pioglitazone in familial combined hyperlipidaemia. *J Intern Med* 259:107–116
19. Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JE, van Rooijen N, Staels B, Kersten S, Müller M 2010 Kupffer cells promote hepatic steatosis via interleukin-1 β -dependent suppression of peroxisome proliferator-activated receptor α activity. *Hepatology* 51:511–522
 20. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Dräger AM, Doni A, van Hinsbergh VW, Stehouwer CD 1999 Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. *Diabetologia* 42:351–357
 21. Reiner AP, Wurfel MM, Lange LA, Carlson CS, Nord AS, Carty CL, Rieder MJ, Desmarais C, Jenny NS, Iribarren C, Walston JD, Williams OD, Nickerson DA, Jarvik GP 2008 Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. *Arterioscler Thromb Vasc Biol* 28:1407–1412
 22. Tack CJ, Ong MK, Lutterman JA, Smits P 1998 Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. *Diabetologia* 41:569–576
 23. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA 2007 Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. *Diabetes Care* 30:89–94
 24. Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T 2008 Treatment with an Interleukin 1 β antibody improves glycemic control in diet-induced obesity. *Cytokine* 44:141–148
 25. Larsen CM, Faulenbach M, Vaag A, Ehse JA, Donath MY, Mandrup-Poulsen T 2009 Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. *Diabetes Care* 32:1663–1668
 26. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF 2007 Interleukin-1 β -induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. *Endocrinology* 148:241–251
 27. Vila AT, Puig L, Fernández-Figueras MT, Laiz AM, Vidal D, Alovera A 2005 Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. *Br J Dermatol* 153:417–423
 28. Pietiläinen KH, Kannisto K, Korshennikova E, Rissanen A, Kaprio J, Ehrenborg E, Hamsten A, Yki-Järvinen H 2006 Acquired obesity increases CD68 and tumor necrosis factor- α and decreases adiponectin gene expression in adipose tissue: a study in monozygotic twins. *J Clin Endocrinol Metab* 91:2776–2781
 29. Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ, Haffner SM 2010 Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). *Diabetes Care* 33:2098–2103



Sign up for eTOC alerts today
to get the latest articles as soon as they are online.

<http://endo.endojournals.org/subscriptions/etoc.shtml>